A significant increase in the number of MDSCs in the peripheral blood of DLBCL patients has also been reported, but only the number of M-MDSCs correlated with the international prognostic index, event-free survival, and the number of circulating Tregs, and IL-10, S100A12, and PD-L1, which are associated with the immunosuppressive effects of MDSCs, were expressed at an increased level in DLBCL patients, while inhibition of these molecules could increase T cell proliferation [73]. The gene discussed is S100A12; the disease is diffuse large B-cell lymphoma.